All News

back, LBP, spine, AS

Broadalumab Efficacy in Axial Spondyloarthritis

d Jack Cush, MD

Broadalumab (Siliq), an anti-interleukin-17 receptor A monoclonal antibody, is currently FDA- approved for use in adults with plaque psoriasis; but a recent trial shows it to be effective in patients with axial spondyloarthritis (axSpA).

Read Article
pompe myopathy glycogen muscle

New, Improved Therapy for Pompe Disease

d Jack Cush, MD

Researchers from the University of Cincinnati Gardner Neuroscience Institute will present data on a new treatment for Pompe disease at the American Academy of Neurology on April 20th; the results show that treatment with avalglucosidase alfa yielded substantial clinical improvements and a more favorable safety profile compared to the current standard of care (alglucosidase alfa).

Read Article
RheumNow Podcast square

RheumNow Podcast – Combination Biologics

d Jack Cush, MD

Dr. Jack Cush serves up this week's news and articles from RheumNow.com.

Read Article
airplane plane seating cabin

Planes, Trains and COVID Distancing

d Jack Cush, MD

MMWR reports the risk of acquiring an infection with SARS-CoV-2 is reduced 23% to 57% when the middle seat was vacant (compared with full aircraft occupancy).

Read Article
COVID.virus_.corona.jpg (keep)

Autoimmune Risk of Death Up during COVID

d Jack Cush, MD

A population-based study in the UK shows that patients with rare autoimmune rheumatic diseases (RAIRD) were 44% more likely to die during the 2020 COVID-19 pandemic (March - April) compared to either the general population or their pre-COVID risk.

Read Article
News Feature: New, Improved Therapy for Pompe Disease https://t.co/dEZ9Y0biHu https://t.co/rXh7fH13rc

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. R Fleischmann "Don't be afraid to use TOFA!" FDA warnings on⬆️ MACE/malign based on 1 study (Pfizer 1133) in high risk patients. Older age, tobacco use are risks for MACE/CV events and cancer. Meta-analyses, registries, clinical trials program do NOT show⬆️ risk #RNL2021 https://t.co/4p9YqyDrGz
k dao KDAO2011 ( View Tweet)
Randomized trial of 206 adults with knee OA found that a web-based exercise intervention supported by text messaging improved knee pain and function at 24 weeks vs web-based information alone. (MCID pain 72.1% vs 42%) https://t.co/h5UaedS4Zm

Links:

Dr. John Cush RheumNow ( View Tweet)

Not in the US, but biosimilar infliximab (CT-P13) is being used subcutaneously in the EU and Canada. Analysis of 2 RCTs shows (compared to IV inflectra or remicade) SC CT-P13 greater DAS28-CRP, CDAI and SDAI response rates. https://t.co/prSVJ0BIdd

Links:

Dr. John Cush RheumNow ( View Tweet)

Have you had the chance to listen to the latest RheumNow podcast on combination biologics? https://t.co/FFtYHhw7Qc https://t.co/YT1h8iL647

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Planes, Trains and COVID Distancing MMWR reports the risk of acquiring an infection with SARS-CoV-2 is reduced 23% to 57% when the middle seat was vacant (compared with full aircraft occupancy). https://t.co/tGs9Go7DhU https://t.co/Gz9L1ERcUU

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: Autoimmune Risk of Death Up during COVID A population-based study in the UK shows patients with RAIRD were 44% more likely to die during the '20 COVID-19 pandemic (Mar - Apr) compared to either the general population or their pre-COVID risk. https://t.co/e1vWOjGglt https://t.co/OIaM3Hx7BO

Links:

Dr. John Cush RheumNow ( View Tweet)
Scoot over small molecule inhibitors, the future might be with nanoparticle targeting for RA! Dr. Fleischmann reviews study on nanoparticle targeting of CCP Ab that showed noninferiority to Tocilizumab #RNL2021 coverage from @KDAO2011

Dr. John Cush RheumNow ( View Tweet)

BRAND NEW PODCAST-- Combination Biologics We talk about the articles featured on RheumNow this week. https://t.co/FFtYHhNJeM https://t.co/XCFMsZ6ttG

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2021 Coverage from Dr. Rachel Tate @uptoTate The good and the bad of HLA B27 iritis from Dr. Wang #RNL2021 -- 90% of patient maintain 20/40 vision or better with treatment -- BUT disease can relapse and can alternate between eyes

Dr. John Cush RheumNow ( View Tweet)

Johns Hopkins myositis clinic: anti-mitochondrial Abs (AMA) found in 5% adult myositis, 1% of juv. myositis pts. AMA assoc. w/ severe muscle weakness, Raynauds, dysphagia, cardiomyopathy & treatment refractory Dz - Screening for cardiac & swallowing https://t.co/oj9kwHgTHf

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: USPSTF - No Need to Screen for Vitamin D Deficiency JAMA has published the new recommendation from the USPSTF stating that screening for vitamin D deficiency is unnecessary and unwarranted in asymptomatic adults. https://t.co/njeBeGgR7f https://t.co/vedK68MS0J

Links:

Dr. John Cush RheumNow ( View Tweet)
ASSAIL-MI trial studied 200 pt with new (<6hr) STEMI-randomized to either PBO or IV 280 mg tocilizumab. While no signif difference in final infarct size (7.2 vs 9.1%; P=.08), TCZ treated pts had better myocardial salvage & less Microvascular obstruction https://t.co/WRRGXCbP5O

Links:

Dr. John Cush RheumNow ( View Tweet)

Non-Hallmark manifestations of dermatomyositis include: panniculitis, diffuse subcutaneous edema, erythroderma, calcinosis, ulceration, flagellate erythema, Wong-type DM, gingival telangiectasias, and the ovoid palatal patch (full read) https://t.co/x6cdP3WDcW

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: NICE Guidelines on Chronic Pain Management Chronic primary pain is pain with no clear underlying cause, or pain (or its impact) that is out of proportion to any observable injury or disease. https://t.co/DV24wKBlEc https://t.co/8uxx4NC9W1

Links:

Dr. John Cush RheumNow ( View Tweet)
×